a Valuedetermined on Day4 specimen, not reportedonpatients record.
The patient, a 3 Va-year-old girl, underwent cardiac transplantation at the University of Michigan Medical Center in 1984. She was treated with digoxin and the concentrations of digoxin in her serum were periodically monitored. During the course of the first post-transplant year she survived several mild episodes of rejection without evidence of major tissue damage. But 14 months post-transplant she was admitted for a suspected rejection episode, which failed to respond to increased administration of cyclosporine. Table 1 shows the patient's digoxin concentrations over the five days following admission, as measured by the routine doubleantibody RIA. On Day 4, the measured value increased to 9 nmoIIL, and the clinical staff was notified of the critical value. Because of the concern over this high concentration of digoxin, another specimen was drawn that evening, and was analyzed by a back-up procedure with the aca ifi (Du Pont Instruments, Wilmington, DE). The value for this specimen, which was drawn 6.5 h after the original specimen, was 2.0 nmolfL, which is within the therapeutic range. A specimen obtained the following morning, and analyzed by the routine RIA procedure, gave a result reported as "greater than the assay limit" of 10.2 nmol/L; the computer-extrapolated result was 25.9 nmol/L. During this entire period the patient showed no signs of digoxin toxicity and the dosage schedule was not altered. Because of the discrepant results, an interference was suspected. A list of concurrently administered medications obtained from the patient's physician included cyclosporine, prednisone, dopamine, captopril, furosemide, co-trimoxazole, and nystatin. None of these medications had been shown to cross react with the double-antibody RIA of digoxin used at the Medical Center.
Upon further discussion with the patient's physician, we learned that on Day 3, 12 h after the second digoxin specimen had been drawn and 12 h before the third specimen was drawn, the patient was started on a 10-day regimen of goat-derived ALG and a 14-day regimen of horsederived A, both administered intravenously at 400 mg/ day. Before the start of this new immunosuppressive therapy the patient was nonreactive to a skin test for sensitivity to goat ALG. This was the patient's first exposure to therapy with exogenous animal immunoglobulin.
With this added information, we suspected that the new treatment might be interfering in some way with the double-antibody RIA technique. All subsequent specimens were therefore analyzed by the aca ifi procedure for digoxin.
Materials and Methods
The routine method for digoxin analysis used at this medical center was an equilibrium RIA procedure, developed in-house, in which sheep anti-digoxin is the primary antibody and donkey anti-sheep gamma globulin is the precipitating reagent. To separate antibody-bound 'I tracer from free tracer, we use a 25 gIL polyethylene glycol solution as a facilitating agent for the precipitation of firstand second-stage antibody complex. The entire reaction takes 20 miii, after which the precipitate is pelleted by centrif#{252}gation, the supernate decanted, and the radioactivity of the bound fraction counted. Another method for digoxin determination is the Du Pont affinity column-mediated immunometric assay (Ac.n) method, which is used at our institution for "Stat" samples during off-shift hours. In this procedure, patient's #{233}erum is concentration of digoxin in the sample (1). In a previous globulins directed against the immunogen. The IgG fraction comparison of these two methods for determination of containing the antibodies against human lymphocytes or digoxin, analysis of covariance with the double-antibody thymocytes is extracted and disaggregated to minimize the procedure as the independent variable and the aca 111 method as the dependent variable yielded a slope of 1.032, a risk of host anaphylactic reaction to the heterologous globulin. The IgG preparation is also adsorbed with human y-intercept of 0.108 nmol/L, and a correlation coefficient of platelets and erythrocyte stroma to minimize crossreactiv-0.95 (n = 64).
ity with other tissue antigens (2) . To determine the source of the discrepancy, we conducted
The major action of ALG is to lyse circulating lymphoseveral experiments. Because of the limited volume of cytes and deplete the T cells from the paracortical region of serum obtained from this pediatric patient, analysis by both the lymph nodes. The B cells in the medullary regions and available methods left insufficient sample for further studgerminal centers are less affected. The T-cell count in ies. Therefore, we attempted to reproduce the postulated peripheral blood remains low for as long as two weeks after conditions observed by using goat-derived ALG (University a course of therapy with ALG/ATG (2). of Minnesota ALG, lot S-T50 27G), goat serum (Vector Labs, ALG/ATG is usually given intravenously over 10 to 14 Burlingame, CA), and horse serum (Gibco, Grand Island, days. Such dosesare less than those administered intramus-NY). We also analyzed 23 specimens from nine transplant cularly, and this route of therapy is both more effective and patients who were all receiving similar medication regiaccompanied by fewer severe anaphylactic reactions (3). mens, including horse-derived A but not goat-derived Disadvantages of therapy with ALG/ATG include increased ALG. None of these specimens yielded measurable digoxin susceptibility to infection, the rare occurrence of an anaphyconcentrations above background by either the RIA or the lactic reaction, and the lack of an in vitro assay to standardaca III method.
ize In the case we report, the exogenous goat immunoglobWe diluted the goat-derived ALG and the goat and horse ulin in the patient's serum interfered in the double-antibody sera with the digoxin assay zero standard to provide a range RIA, the 500 mg/L samples showing an apparent digoxin of goat and horse IgG that included the concentration of 500 concentration of >10.3 nmol/L for both the goat serum and mg/L. We then assayed these samples as unknowns in the the goat-derived ALG (Fable 2). In fact, the goat-derived RIA procedure; the results are depicted in Table 2. ALG shows an apparent digoxin concentration of 0.4 nmol/L Discussion for IgG at the 50 mg/L dilution, which is well below the concentration of goat IgG calculated to be present in the Heterologous ALG and A are potent immunosupprespatient's specimen that first yielded questionable results. sive agents with proven effectiveness for both suppressing As previously described, the precipitating or second antiand reversing acute rejection episodes. Most forms of ALG body in the routine digoxin RIA procedure is donkey antiand A are produced by immunizing a horse, goat, or sheep gamma globulin. The concentrations of the reagents rabbit with an enriched preparation of human lymphocytes are set to maintain a rough equivalence in the incubation from cultured lymphoblasts, or from human thymic tissues, and collecting the hyperimmune serum containing immunetube, to permit immunoprecipitation. Cross reactivity between the donkey anti-sheep gamma globulin and the goat ALG would explain the results observed in the patient's specimen as well as in the various dilutions of goat serum. In the presence of excess gamma globulins, as would occur with treatment of the patient with ALG/ATG, the equivalence of the first and second antibody concentration would be perturbed, enhancing the formation of soluble complexes. These soluble complexes would not form a pellet under the usual centrifugation procedure and a large quantity of 'Ilabeled digoxin bound to sheep anti-digoxin would remain in solution. As a result, the tracer normally contained in the immunoprecipitated antigen-antibody complex would be decanted in the supernate. The fewer counts in the pellet would be interpreted as an increased concentration of digoxin in the patient's specimen.
Unlike double-antibody assay methods, the Du Pont methodology does not rely on an antigen-antibody precipitation reaction for the separation of bound and free analytes. Instead, an affinity column procedure is used to remove the anti-digoxin--enzyme conjugate that has not reacted with digoxin. Binding of digoxin to the conjugate inhibits binding to the affinity column and allows the conjugate to pass through the column and into the test pack. The presence of exogenous animal immunoglobulins therefore should not cause an interference like that observed in the doubleantibody RIA.
Because the half-life of goat ALG in plasma is approximately 5.7 (±3) days, assay interference could be increased as the immunosuppressive therapy continues and the titer of exogenous immunoglobulin increases. This was, in fact, the case, as demonstrated in Table 1 . The digoxin value increased from 9.0 nmol/L on Day 4 to an extrapolated value of 25.9 nmolJL on Day 5 with no change in the digoxin dosage. Immunosuppressive therapy with ALG and A will likely increase in the future. The potential for an interference similar to that described here exists for any immunoassay involving immunoprecipitation separation techniques, regardless of the analyte. Medical and clinical laboratory personnel must be aware of this possibility. Because of the speed with which this problem was identified in our laboratory, there was no adverse effect on the patient. However, the change in treatment that might have been implemented on the basis of the apparent toxic concentration of digoxin could have produced serious negative consequences for this patient.
